Background Human T-lymphotropic virus 1 (HTLV-1) infection has an especially high
prevalence in Japan. Transmission has been confirmed in infancy through breastfeeding; …

The present study sought to elucidate the prognosis of adult T‐cell leukemia–lymphoma
(ATL) patients receiving mogamulizumab, a defucosylated anti‐CCR 4 monoclonal …

Human T-cell leukemia virus type 1 (HTLV-1) is the causative infectious agent of adult T-cell
leukemia/lymphoma (ATL) and chronic neurological disease. The disparity between …

The discovery of CARMA1 gain-of-function mutations in T-cell malignancies and BENTA
patients, as well as the association of CARMA1 and MALT1 mutations with human …

Over the years, cancer has been affecting the lives of many people globally and it has
become one of the most studied diseases. Despite the efforts to understand the cell …

Adult T-cell leukemia-lymphoma (ATL) is an aggressive hematological malignancy of CD4+
T cells transformed by human T-cell lymphotropic virus-1 (HTLV-1). Most HTLV-1–infected …

There is a growing understanding that several infectious agents are acquired in early life
and this is the reason why available vaccines target the new born, infants, and adolescents …

Abstract Monitoring of Immune Responses Following Mogamulizumab-Containing
Treatment in Patients with Adult T-Cell Leukemia-Lymphoma (ATL)(MIMOGA) is a …

Adult T-cell leukemia/lymphoma (ATLL) is an aggressive disease caused by infection with
human T-cell leukemia virus type 1 (HTLV-1). Successful treatment is limited by resistance to …

Chemotherapy in combination with mogamulizumab (Mog) was approved in Japan in 2014
for untreated aggressive adult T‐cell leukaemia‐lymphoma (ATL), but the survival benefit …